|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Cotellic
|
|
gptkbp:activities
|
BRAF inhibitor
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2011
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Zelboraf
|
|
gptkbp:class
|
gptkb:Cloud_Computing_Service
|
|
gptkbp:clinical_trial
|
gptkb:BRIM-2
gptkb:BRIM-3
gptkb:BRIM-4
Phase III
advanced melanoma
BRIM-1
|
|
gptkbp:contraindication
|
severe liver impairment
hypersensitivity to vemurafenib
|
|
gptkbp:discovered_by
|
gptkb:Genentech
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
vemurafenib
|
|
gptkbp:indication
|
gptkb:BRAF_V600_E_mutation-positive_melanoma
|
|
gptkbp:ingredients
|
C23 H27 Cl F2 N2 O2 S
|
|
gptkbp:interacts_with
|
CY P3 A4 inducers
CY P2 C9 inhibitors
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_used_for
|
treatment of melanoma
|
|
gptkbp:lifespan
|
57 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:Roche
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pharmacokinetics
|
highly protein-bound
inhibits cell proliferation
induces apoptosis
|
|
gptkbp:produced_by
|
marketed
|
|
gptkbp:research_areas
|
oncology
pharmacogenomics
|
|
gptkbp:safety_features
|
hepatotoxicity
QT prolongation
ocular toxicity
risk of new malignancies
|
|
gptkbp:side_effect
|
gptkb:fandom
fatigue
headache
nausea
vomiting
diarrhea
joint pain
constipation
skin rash
hypoglycemia
photosensitivity
cardiac arrhythmias
alopecia
hyperglycemia
thromboembolism
hypersensitivity reactions
elevated liver enzymes
musculoskeletal pain
pruritus
|
|
gptkbp:targets
|
gptkb:BRAF_V600_E_mutation
|